Business Credit Business Travel Franchising Personal Finance Sales & Selling Technology Women in Business Careers E-Commerce & Internet Finance & Accounting Labor & Employment Management Marketing & Advertising Operations Starting a Business > See All

by Title A-H by Title I-P by Title Q-Z > See All

Business Intelligence Small Business Blog Business Planning E-Commerce & Internet Finance & Accounting Home-Based Business Human Resources & Employment Management & Leadership Marketing & Advertising Operations Sales Technology Women in Business > See All

Hiring & Firing Intellectual Property Internet & Technology Legal Mergers & Acquisitions Money & Fundraising Real Estate/Landlord-Tenant Sales & Marketing Starting a Business Business Guides Forms Kits > See All

Construction Medical Practices Restaurants Retail Trade Manufacturing Real Estate Wholesale Trade > See All

Accounting Advertising & Marketing Computers & Software Financial Services Human Resources Internet & Online Management Small Business > See All

Business Exchange Business Answers Buyer's Guides Franchise Opportunities Glossary Trials & Downloads Partner Resources Podcast Library Quote Center Video Library Web Site Tools > See All

TB ALLIANCE/GLAXOSMITHKLINE TO DEVELOP TB THERAPIES.

Publication: Worldwide Biotech
Date: Sunday, May 1 2005

The Global Alliance for TB Drug Development (TB Alliance) and GlaxoSmithKline (FTSE/NYSE: GSK) are pursuing a joint drug discovery program to improve the treatment of tuberculosis (TB). The program substantially enhances the worldwide TB drug pipeline by adding several novel classes of compounds that use new mechanisms of action.

The joint research program consists of a portfolio of four projects intended to yield new compounds that attack Mycobacterium tuberculosis (M. tb) on multiple levels. Drug candidates arising from these projects could shorten the treatment time

To read the rest of this article, click here to take a free trial

In addition, make sure to read these premium articles also available with your free trial:

AVEXA IN-LICENSES PHASE II HIV DRUG FROM SHIRE.

Research and development biotechnology company Avexa Limited (ASX: AVX) has in-licensed the Phase II HIV drug - SPD754 - from global specialty pharmaceutical company Shire ......

Drug market will dictate manufacturing evolution.(Brief Article)

Branded drug makers continue to enjoy double-digit revenue growth rates and healthy profits, but manufacturing bottlenecks strangle their efforts, according to Forrester Research Inc. If ......

Scheduling a cure: the pharmaceuticals industry presents unique...

In the beginning, there was the cure, and the cure was in the hands of the chemists. But eventually the process of getting the cure ......

BIOLINERX LICENSES PEPTIDE FOR INFLAMMATORY DISEASES.

BioLineRx Ltd.(TASE:BLRX), Israel's leading drug development company, has signed a worldwide exclusive license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, ......

MERRIMACK COMPLETES ENROLLMENT FOR MM-093 PHASE IIA.

Merrimack Pharmaceuticals, Inc., Cambridge, Mass., has completed enrollment for a Phase IIa pilot study in patients with rheumatoid arthritis with its immunomodulatory drug candidate, MM-093, ......

Stock Strategist: Is Amgen Ready for a Dividend?

Byline: Karen Andersen Jan. 8--As a quick screen for dividend-paying drug stocks reveals, biotechs and dividend yields don't often mix. There are several well-known reasons ......

PEPLIN ACQUIRES PORTFOLIO OF POTENTIAL THERAPEUTIC PRODUCTS.

Peplin Biotech Ltd [ASX: PEP], Brisbane, Australia, has acquired a promising portfolio of potential therapeutic products comprising new synthetic, engineered polyunsaturated fatty acid (EPUFA) compounds....

ROCHE/GLYCART TO DISCOVER NEW THERAPEUTIC ANTIBODIES.

Roche and GLYCART have signed an agreement to discover next-generation therapeutic antibodies using GlycoMAbTM technology. Roche will have the option to develop and market worldwide ......

Stock Strategist: A Stable Niche in Big Pharma.

Byline: Emil Lee Feb. 13--Many investors would love to experience the explosive upside that biotech and pharmaceutical companies can offer when major blockbuster drugs get ......

VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), Cambridge, Mass., and Mitsubishi Pharma Corporation have signed an agreement to develop and commercialize VX-950, Vertex's investigational oral protease inhibitor ......

T T T

Digg It

del.icio.us

Related Resources

Free AllBusiness Articles

Patent granted for preparation of HIV drug.

The United States Patent and Trademark Office issued a broad patent to Sarawak MediChem Pharmaceuticals of (Woodridge, IL), bolstering the company's proprietary position in the use of calanolides as potential anti-viral drugs, the company announced. Sarawak MediChem Pharmaceuticals is a 50/50 joint venture between the State Government of Sarawak in ......

Nutra Pharma Announces Successful Completion of Joint Venture Meetings in China.

BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its drug discovery division, ReceptoPharm, has successfully completed initial discussions with Zhong Xin Dong Tai Co., Ltd. (Nanogene Biotechnology) to develop RPI-MN for the Chinese market....

The WTO dispute settlement understanding: An unlikely weapon in the fight against AIDS

I. INTRODUCTION One of the most controversial aspects of the World Trade Organization (WTO) is its trade policy governing pharmaceutical products that treat AIDS and other diseases.1 Critics contend that the WTO unreasonably restricts the trade of pharmaceuticals in order to protect the profit margin of western drug producers at ......

Improving third world health: to display social responsibility, CEOs must respond to urgent needs.

Corporate responsibility is a complex issue, especially when Wall Street focuses on short-term profit growth. Delivering excellent performance on a regular basis is indeed an imperative, but it is no longer sufficient. Society expects corporations to behave in ethical and socially responsible ways. Today, more than ever, corporate social responsibility ......

Victory and betrayal: the third world takes on the rich countries in the struggle for access to medicines. (Patently Abusive).

WITH THE RAVAGES OF AIDS AND OTHER ILLNESSES wreaking untold misery in developing countries and high drug prices preventing sick people from receiving lifesaving treatments, pressure has mounted to remove some of the monopoly protections in developing nations that keep drug prices so high. But the pharmaceutical companies do not ......

TRIPS, pharmaceuticals, developing countries, and the Doha "solution"

Pharmaceutical prices in the developing world have been much in the news lately. The bulk of the attention stems from the HIV/AIDS epidemic which affects many developing countries acutely, and where much of the infected population is said to be unable to obtain effective therapies because of their prohibitive cost....

Brazil: at the United Nations AIDS conference in Spain last month, Brazil announced a plan to help developing countries manufacture generic AIDS drugs. (Region Watch).

At the United Nations AIDS conference in Spain last month, Brazil announced a plan to help developing countries manufacture genetic AIDS drugs. This initiative is an expansion of Brazil's treatment plan for its own citizens, introduced in 1997. The Brazilian government manufactures 15 different types of AIDS drugs and is ......

Blogs

Putting the "tele" back in telemedicine

Cellphones are emerging as the vehicle of choice to transmit and receive patient data and information to remote physicians.

Venture Capital Bill Rockets Out of Committee

The House Small Business Committee has quickly approved a bill to let firms owned by venture capital companies participate in federal small business programs, much to the dismay of SMB advocates.

SBA - Office of Technology - SBIR/STTR - SBIR and STTR Programs

SBA - Office of Technology - SBIR/STTR - SBIR and STTR Programs : "Description of the Small Business Innovation Research Program (SBIR)": "SBIR is a highly competitive program that encourages small business to explore their technological potential and provides the incentive to profit from its commercialization. By including qualified ......

Budget Cuts, Mismanagement Muddle SBIR Grants

The government's Small Business Innovation Research program has funded important research. But budget cuts and mismanagement have taken their toll on the program.

All Bloggers

TB ALLIANCE/GLAXOSMITHKLINE TO DEVELOP TB THERAPIES.

In addition, make sure to read these premium articles also available with your free trial:

Related Resources

Free AllBusiness Articles

Blogs

Sponsored Links